HomeCompareEVKIF vs MRK

EVKIF vs MRK: Dividend Comparison 2026

EVKIF yields 6.40% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EVKIF wins by $956.00 in total portfolio value
10 years
EVKIF
EVKIF
● Live price
6.40%
Share price
$18.60
Annual div
$1.19
5Y div CAGR
1.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.7K
Annual income
$1,175.11
Full EVKIF calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — EVKIF vs MRK

📍 EVKIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEVKIFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EVKIF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EVKIF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EVKIF
Annual income on $10K today (after 15% tax)
$543.82/yr
After 10yr DRIP, annual income (after tax)
$998.84/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, EVKIF beats the other by $191.10/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EVKIF + MRK for your $10,000?

EVKIF: 50%MRK: 50%
100% MRK50/50100% EVKIF
Portfolio after 10yr
$31.2K
Annual income
$1,062.70/yr
Blended yield
3.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

EVKIF
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
2.0
Piotroski
6/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EVKIF buys
0
MRK buys
0
No recent congressional trades found for EVKIF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEVKIFMRK
Forward yield6.40%3.25%
Annual dividend / share$1.19$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR1.7%8.2%
Portfolio after 10y$31.7K$30.7K
Annual income after 10y$1,175.11$950.29
Total dividends collected$9.0K$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: EVKIF vs MRK ($10,000, DRIP)

YearEVKIF PortfolioEVKIF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,351$650.66$11,192$351.54+$159.00EVKIF
2$12,847$701.96$12,524$392.70+$323.00EVKIF
3$14,502$755.16$14,015$438.65+$487.00EVKIF
4$16,327$810.18$15,682$489.96+$645.00EVKIF
5$18,337$866.98$17,547$547.23+$790.00EVKIF
6$20,546$925.47$19,632$611.16+$914.00EVKIF
7$22,970$985.60$21,963$682.53+$1.0KEVKIF
8$25,625$1,047.30$24,571$762.18+$1.1KEVKIF
9$28,529$1,110.49$27,486$851.08+$1.0KEVKIF
10$31,701$1,175.11$30,745$950.29+$956.00EVKIF

EVKIF vs MRK: Complete Analysis 2026

EVKIFStock

Evonik Industries AG engages in the specialty chemicals business. It operates through Specialty Additives, Nutrition & Care, Smart Materials, Performance Materials, and Technology & Infrastructure segments. The Specialty Additives segment provides polyurethane additives, organically modified silicones, isophorones, epoxy curing agents, oil additives, fumed silicas, matting agents, TAA and TAA derivatives, and acetylenic diol-based surfactants for consumer goods and specialized industrial applications. The Nutrition & Care segment offers amphoteric surfactants, ceramides, phytosphingosines, oleochemicals, quaternary derivatives, amino acids and amino acid derivatives, synthesis products, pharmaceutical polymers, and DL-methionine for use in consumer goods, animal nutrition, and healthcare products. The Smart Materials segment provides hydrogen peroxide, peracetic acid, activated nickel catalysts, precious metal powder catalysts, oil and fat hydrogenation catalysts, amorphous polyalphaolefins, polybutadienes, polyester resins, thermoplastic and reactive methacrylate resins, PEEK, polyamide 12, organosilanes, chlorosilanes, fumed silicas, fumed metal oxides, and precipitated silicas for the automotive, paints, coatings, adhesives, construction, and various other sectors. The Performance Materials segment produces polymer materials and intermediates, including butene-1, DINP, isononanol, cyanuric chloride, alkoxides, and superabsorbent for rubber, plastics, and automotive industries. The Technology & Infrastructure segment provides site management, utilities and waste management, technical, process technology, engineering, and logistics services. It operates in the Asia-Pacific, Europe, the Middle East, Africa, Central and South America, and North America. The company was founded in 1873 and is headquartered in Essen, Germany. Evonik Industries AG is a subsidiary of RAG-Stiftung.

Full EVKIF Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this EVKIF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EVKIF vs SCHDEVKIF vs JEPIEVKIF vs OEVKIF vs KOEVKIF vs MAINEVKIF vs JNJEVKIF vs ABBVEVKIF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.